The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The grants are expected to be received over the next three years, commencing March 2022
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
With ValGenesis VLMS, change control driven validation activities are reduced from weeks to mere hours, and the company gains faster access to detailed metrics that help reduce costs and cycle time
Subscribe To Our Newsletter & Stay Updated
